FY2026 EPS Forecast for C4 Therapeutics Lifted by Analyst

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Equities researchers at Brookline Capital Markets boosted their FY2026 earnings estimates for shares of C4 Therapeutics in a report issued on Thursday, November 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn ($0.69) per share for the year, up from their prior forecast of ($0.80). The consensus estimate for C4 Therapeutics’ current full-year earnings is ($0.81) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics’ Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($1.57) EPS.

A number of other research firms have also issued reports on CCCC. Evercore lowered C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Thursday, October 15th. JPMorgan Chase & Co. initiated coverage on C4 Therapeutics in a report on Friday, October 9th. They set an “overweight” rating and a $10.00 price target on the stock. Lake Street Capital assumed coverage on C4 Therapeutics in a research report on Wednesday, October 28th. They issued a “buy” rating and a $11.00 price target on the stock. Finally, Wall Street Zen lowered C4 Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

C4 Therapeutics Trading Up 1.6%

C4 Therapeutics stock opened at $3.15 on Tuesday. C4 Therapeutics has a twelve month low of $1.69 and a twelve month high of $5.17. The stock’s fifty day simple moving average is $3.21 and its 200-day simple moving average is $3.23. The firm has a market capitalization of $387.54 million, a P/E ratio of -4.37 and a beta of 3.16.

C4 Therapeutics (NASDAQ:CCCC) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. The company had revenue of $8.47 million during the quarter, compared to analysts’ expectations of $8.52 million. C4 Therapeutics had a negative net margin of 289.44% and a negative return on equity of 45.45%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Velan Capital Investment Management LP purchased a new stake in shares of C4 Therapeutics during the 2nd quarter worth $2,662,000. Renaissance Technologies LLC grew its stake in shares of C4 Therapeutics by 53.6% during the first quarter. Renaissance Technologies LLC now owns 2,461,815 shares of the company’s stock worth $6,475,000 after purchasing an additional 859,235 shares in the last quarter. Wasatch Advisors LP increased its holdings in C4 Therapeutics by 18.9% in the second quarter. Wasatch Advisors LP now owns 3,522,644 shares of the company’s stock valued at $16,451,000 after buying an additional 560,883 shares during the last quarter. Stempoint Capital LP purchased a new position in C4 Therapeutics in the first quarter valued at $1,192,000. Finally, Headlands Technologies LLC purchased a new position in C4 Therapeutics in the second quarter valued at $719,000. Institutional investors and hedge funds own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity.

C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.